Cargando…

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes

IMPORTANCE: Evidence suggests that patients with human epidermal growth factor receptor 2–positive (ERBB2+ [formerly HER2+]) metastatic breast cancer (MBC) have different clinical characteristics and outcomes according to their hormone receptor (HR) status. The place of endocrine therapy (ET) for pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carausu, Marcela, Carton, Matthieu, Diéras, Véronique, Petit, Thierry, Guiu, Séverine, Gonçalves, Anthony, Augereau, Paule, Ferrero, Jean Marc, Levy, Christelle, Ung, Mony, Desmoulins, Isabelle, Debled, Marc, Bachelot, Thomas, Pistilli, Barbara, Frenel, Jean-Sébastien, Mailliez, Audrey, Chevrot, Michaël, Cabel, Luc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856509/ https://www.ncbi.nlm.nih.gov/pubmed/36520434 http://dx.doi.org/10.1001/jamanetworkopen.2022.47154

Ejemplares similares

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
por: François-Martin, Hélène, et al.
Publicado: (2023)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
por: Carausu, Marcela, et al.
Publicado: (2022)

Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
por: Vasseur, Antoine, et al.
Publicado: (2022)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database
por: Mailliez, Audrey, et al.
Publicado: (2022)

Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
por: Mallet, Amélie, et al.
Publicado: (2022)

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
por: Darlix, Amélie, et al.
Publicado: (2019)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
por: Moinard-Butot, Fabien, et al.
Publicado: (2022)

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
por: Frank, Sophie, et al.
Publicado: (2020)

Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
por: Carausu, M., et al.
Publicado: (2021)

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
por: Sirieix, Junien, et al.
Publicado: (2020)

Impact of body mass index on overall survival in patients with metastatic breast cancer
por: Saleh, Khalil, et al.
Publicado: (2020)

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
por: Grinda, T., et al.
Publicado: (2021)

Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes
por: Billaud, Amandine, et al.
Publicado: (2021)

ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
por: Carausu, Marcela, et al.
Publicado: (2019)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
por: Cabel, Luc, et al.
Publicado: (2021)

Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
por: Augereau, Paule, et al.
Publicado: (2017)

Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?
por: Grinda, T., et al.
Publicado: (2023)

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
por: Lerebours, Florence, et al.
Publicado: (2020)

Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
por: Bertho, Marion, et al.
Publicado: (2021)

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer
por: Bortolini Silveira, Amanda, et al.
Publicado: (2021)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
por: Alexandre, Marie, et al.
Publicado: (2019)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling
por: Wandinger, Sebastian K., et al.
Publicado: (2016)

VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study
por: Gal, Jocelyn, et al.
Publicado: (2020)

Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study
por: Alhenc-Gelas, Marion, et al.
Publicado: (2021)

CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
por: Gougis, P., et al.
Publicado: (2019)

Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature
por: Carausu, Marcela, et al.
Publicado: (2019)

Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda
por: Sinayobye, Jean d’Amour, et al.
Publicado: (2014)

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole
por: Gunzer, Katharina, et al.
Publicado: (2016)

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
por: Lefebvre, Celine, et al.
Publicado: (2016)

HR TEAM
por: Brice, Maximilien
Publicado: (2015)

HR Organigramme
por: Favre, A
Publicado: (2001)

Organigramme HR
por: Favre, A
Publicado: (2011)

HR Explorer
por: Möller, M, et al.
Publicado: (1997)

Careers HR
por: Marcastel, Fabienne CERN Graphic Design service
Publicado: (2013)

Disproportion in T-cell subpopulations in immunodeficient mutant hr/hr mice
Publicado: (1979)

Cannot write session to /tmp/vufind_sessions/sess_ob5elrnmpbac1hakacib7aq749